Trial Profile
Phase I Study of CDK4/6 Inhibitor Ribociclib (LEE011) Combined With Gemcitabine in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Jan 2023
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Ribociclib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 08 Sep 2022 Status changed from active, no longer recruiting to completed.
- 06 Oct 2021 Planned primary completion date changed from 9 Aug 2021 to 9 Aug 2022.
- 29 Sep 2020 Planned End Date changed from 9 Aug 2021 to 9 Aug 2022.